SSY Group Gains China Approval for New Drugs

  Published 10 months ago

SSY Group Ltd. received Chinese regulatory approval for two new pharmaceutical products: Dronedarone Hydrochloride Tablets (antiarrhythmic) and Gabexate Mesylate for Injection (pancreatitis treatment). This marks a significant advancement for the company.

  • Approval for antiarrhythmic drug, Dronedarone.
  • Gabexate Mesylate approved for pancreatitis.
  • Positive step for SSY Group's development.

You might like these

UCO Bank Appoints New CFO, Sumit Khandelwal

US Markets Mixed Amid Debt & Tax Concerns

Zydus Gets USFDA Nod for Plant

JD Cables Wins Rs9.8 Crore XLPE Deal

Zaggle Teams Up with DTDC Express for 5-Year Spend Management Deal

India's Textiles Task Force Aims to Boost Exports

Epack Prefab Shares Strong Debut

News that matters the most ⚡